LSBio
LSBio
Products
Services
Research Areas
Resources
Contact Us
Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting immunostaining in relation to complex human pathologies.

Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding. Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".

LSBio
2401 Fourth Avenue Suite 900
Seattle WA 98121

Phone: 866-819-4732 (Toll Free North America)
206-374-1102 (International)

Fax: 866-206-6909 (Toll Free North America)
206-577-4565 (International)

How to Buy - Details about how to buy our products.

Orders@LSBio.com - To submit a new order.

Customer.Support@LSBio.com - To submit questions about existing orders, pricing, availability, bulk quotes, proforma invoice requests, or other billing issues.

Technical.Support@LSBio.com - To request technical information requests about an LSBio product or its application.

Sales@LSBio.com - To request information about fee-for-service contract IHC studies, IHC reports, distribution agreements, or general business development.

Worldwide Distributors List - To find your local distributor if you're not within the United States.
Products
Services
Research Areas
Resources
Contact Us

GSK3A / GSK3 Alpha Antibody (phospho-Ser21) LS-C18920

Note: This antibody replaces LS-C66826, LS-C66825
GSK3 Alpha antibody LS-C18920 is an unconjugated rabbit polyclonal antibody to human GSK3 Alpha (GSK3A). Validated for ELISA and WB.
Catalog
Size
Price
LS-C18920-100
100 µg (1.28 mg/ml)
$425
Description
GSK3 Alpha antibody LS-C18920 is an unconjugated rabbit polyclonal antibody to human GSK3 Alpha (GSK3A). Validated for ELISA and WB.
Target
Human GSK3A / GSK3 Alpha
Host
Rabbit
Reactivity
Human (tested or 100% immunogen sequence identity)
Clonality
Polyclonal
Conjugations
Unconjugated
Purification
Immunoaffinity purified
Modifications
Unmodified
Applications
  • Western blot (1:500 - 1:3000)
  • ELISA (1:2000 - 1:10000)
Immunogen
Synthetic peptide from human GSK3A / GSK3 Alpha.
Epitope
pSer21
Specificity
aa 16-25 of human GSK3 alpha.
Usage
This affinity-purified antibody has been tested for use in ELISA and by western blot. Specific conditions for reactivity should be optimized by the end user. Expect a band approximately 52 kD in size corresponding to GSK3A by western blotting in the appropriate cell lysate or extract. Less than 1 % reactivity is observed against the non-phosphorylated form of the immunizing peptide. This antibody is phospho specific for pS21 of GSK3A.
Presentation
0.02 M Potassium Phosphate, pH 7.2, 0.15 M NaCl, 0.01% Sodium Azide
Storage
Store vial at -20°C prior to opening. Dilute only prior to immediate use. For extended storage aliquot contents and freeze at -20°C or below. Avoid freeze-thaw cycles.
Restrictions
For research use only.
About GSK3A / GSK3 Alpha
P49840 NM_019884 NP_063937.2

Popular GSK3A / GSK3 Alpha Products

Antibody
Species: Mouse
Applications: IHC, Western blot, ELISA
Antibody
Species: Drosophila, Insect
Applications: ICC, Western blot
Antibody
Species: Human
Applications: Flow Cytometry
Antibody
Species: Human, Mouse, Rat
Applications: IHC, Western blot
Antibody
Species: Human, Monkey, Mouse, Rat, Bovine, Zebrafish, Drosophila
Applications: IHC, Immunofluorescence, Western blot

Publications (0)


Customer Reviews (0)


Images

Western blot

Anti-GSK3A Antibody - Western Blot. Western blot of Affinity Purified anti-GSK3A antibody shows detection of a 52 kD band corresponding to human GSK3A in various human derived 293T cell extracts. Cells were serum starved for 24 h. Lane 1: control, Lane 2: treated with IGF-1 (100 ng/ml) for 20 min, Lane 3: pre-treated with 10 uM LY294002 (selective PI3K inhibitor) and treated with IGF-1 (100 ng/ml) for 20 min. Lane 1 shows some baseline GSK3A reactivity that is intensified upon stimulation (lane2) and diminished when an inhibitor is added (lane 3). Approximately 20 ug of lysate was run on a SDS-PAGE and transferred onto nitrocellulose followed by reaction with a 1:1000 dilution of anti-GSK3A antibody. Signal was detected using standard techniques. Personal communication, Angela Carter, Experimental Therapeutics, Ontario Cancer Inst, Toronto, Canada.
Anti-GSK3A Antibody - Western Blot. Western blot of Affinity Purified anti-GSK3A antibody shows detection of a 52 kD band corresponding to human GSK3A in various human derived 293T cell extracts. Cells were serum starved for 24 h. Lane 1: control, Lane 2: treated with IGF-1 (100 ng/ml) for 20 min, Lane 3: pre-treated with 10 uM LY294002 (selective PI3K inhibitor) and treated with IGF-1 (100 ng/ml) for 20 min. Lane 1 shows some baseline GSK3A reactivity that is intensified upon stimulation (lane2) and diminished when an inhibitor is added (lane 3). Approximately 20 ug of lysate was run on a SDS-PAGE and transferred onto nitrocellulose followed by reaction with a 1:1000 dilution of anti-GSK3A antibody. Signal was detected using standard techniques. Personal communication, Angela Carter, Experimental Therapeutics, Ontario Cancer Inst, Toronto, Canada.

Western blot

Anti-GSK3A Antibody - Western Blot. Western blot of Affinity Purified anti-GSK3A antibody shows detection of a 52 kD band corresponding to human GSK3A in various human derived 293T cell extracts. Cells were serum starved for 24 h. Lane 1: control, Lane 2: treated with IGF-1 (100 ng/ml) for 20 min, Lane 3: pre-treated with 10 uM LY294002 (selective PI3K inhibitor) and treated with IGF-1 (100 ng/ml) for 20 min. Lane 1 shows some baseline GSK3A reactivity that is intensified upon stimulation (lane2) and diminished when an inhibitor is added (lane 3). Approximately 20 ug of lysate was run on a SDS-PAGE and transferred onto nitrocellulose followed by reaction with a 1:1000 dilution of anti-GSK3A antibody. Signal was detected using standard techniques. Personal communication, Angela Carter, Experimental Therapeutics, Ontario Cancer Inst, Toronto, Canada.
Anti-GSK3A Antibody - Western Blot. Western blot of Affinity Purified anti-GSK3A antibody shows detection of a 52 kD band corresponding to human GSK3A in various human derived 293T cell extracts. Cells were serum starved for 24 h. Lane 1: control, Lane 2: treated with IGF-1 (100 ng/ml) for 20 min, Lane 3: pre-treated with 10 uM LY294002 (selective PI3K inhibitor) and treated with IGF-1 (100 ng/ml) for 20 min. Lane 1 shows some baseline GSK3A reactivity that is intensified upon stimulation (lane2) and diminished when an inhibitor is added (lane 3). Approximately 20 ug of lysate was run on a SDS-PAGE and transferred onto nitrocellulose followed by reaction with a 1:1000 dilution of anti-GSK3A antibody. Signal was detected using standard techniques. Personal communication, Angela Carter, Experimental Therapeutics, Ontario Cancer Inst, Toronto, Canada.

Western blot

Anti-GSK3A Antibody - Western Blot. Western blot of Affinity Purified anti-GSK3A antibody shows detection of a 52 kD band corresponding to human GSK3A in various human derived 293T cell extracts. Cells were serum starved for 24 h. Lane 1: control, Lane 2: treated with IGF-1 (100 ng/ml) for 20 min, Lane 3: pre-treated with 10 uM LY294002 (selective PI3K inhibitor) and treated with IGF-1 (100 ng/ml) for 20 min. Lane 1 shows some baseline GSK3A reactivity that is intensified upon stimulation (lane2) and diminished when an inhibitor is added (lane 3). Approximately 20 ug of lysate was run on a SDS-PAGE and transferred onto nitrocellulose followed by reaction with a 1:1000 dilution of anti-GSK3A antibody. Signal was detected using standard techniques. Personal communication, Angela Carter, Experimental Therapeutics, Ontario Cancer Inst, Toronto, Canada.
Anti-GSK3A Antibody - Western Blot. Western blot of Affinity Purified anti-GSK3A antibody shows detection of a 52 kD band corresponding to human GSK3A in various human derived 293T cell extracts. Cells were serum starved for 24 h. Lane 1: control, Lane 2: treated with IGF-1 (100 ng/ml) for 20 min, Lane 3: pre-treated with 10 uM LY294002 (selective PI3K inhibitor) and treated with IGF-1 (100 ng/ml) for 20 min. Lane 1 shows some baseline GSK3A reactivity that is intensified upon stimulation (lane2) and diminished when an inhibitor is added (lane 3). Approximately 20 ug of lysate was run on a SDS-PAGE and transferred onto nitrocellulose followed by reaction with a 1:1000 dilution of anti-GSK3A antibody. Signal was detected using standard techniques. Personal communication, Angela Carter, Experimental Therapeutics, Ontario Cancer Inst, Toronto, Canada.

Western blot

Anti-GSK3A Antibody - Western Blot. Western blot of Affinity Purified anti-GSK3A antibody shows detection of a 52 kD band corresponding to human GSK3A in various human derived 293T cell extracts. Cells were serum starved for 24 h. Lane 1: control, Lane 2: treated with IGF-1 (100 ng/ml) for 20 min, Lane 3: pre-treated with 10 uM LY294002 (selective PI3K inhibitor) and treated with IGF-1 (100 ng/ml) for 20 min. Lane 1 shows some baseline GSK3A reactivity that is intensified upon stimulation (lane2) and diminished when an inhibitor is added (lane 3). Approximately 20 ug of lysate was run on a SDS-PAGE and transferred onto nitrocellulose followed by reaction with a 1:1000 dilution of anti-GSK3A antibody. Signal was detected using standard techniques. Personal communication, Angela Carter, Experimental Therapeutics, Ontario Cancer Inst, Toronto, Canada.
Anti-GSK3A Antibody - Western Blot. Western blot of Affinity Purified anti-GSK3A antibody shows detection of a 52 kD band corresponding to human GSK3A in various human derived 293T cell extracts. Cells were serum starved for 24 h. Lane 1: control, Lane 2: treated with IGF-1 (100 ng/ml) for 20 min, Lane 3: pre-treated with 10 uM LY294002 (selective PI3K inhibitor) and treated with IGF-1 (100 ng/ml) for 20 min. Lane 1 shows some baseline GSK3A reactivity that is intensified upon stimulation (lane2) and diminished when an inhibitor is added (lane 3). Approximately 20 ug of lysate was run on a SDS-PAGE and transferred onto nitrocellulose followed by reaction with a 1:1000 dilution of anti-GSK3A antibody. Signal was detected using standard techniques. Personal communication, Angela Carter, Experimental Therapeutics, Ontario Cancer Inst, Toronto, Canada.

Requested From: United States
Date Requested: 4/21/2019
Get Social With Us!
Follow us on Facebook Follow us on Google+ Follow us on LinkedIn PSL Alliance Member
Copyright © 2019 LifeSpan BioSciences, Inc. All Rights Reserved Privacy Policy